Vivos Therapeutics (VVOS) Net Cash Flow Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | -562.50% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -564.44% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -394.13% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 76.43% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | -31.84% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 57.36% |
| 10 | Vivos Therapeutics | 8.16 Mn | 5.93 Mn | 3.06 Mn | 102.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.07% |
| Dec 31, 2025 | -1,878.43% |
| Sep 30, 2025 | -128.72% |
| Jun 30, 2025 | -319.25% |
| Mar 31, 2025 | -504.75% |
| Dec 31, 2024 | -107.25% |
| Sep 30, 2024 | 79.96% |
| Jun 30, 2024 | 236.47% |
| Mar 31, 2024 | -72.85% |
| Dec 31, 2023 | 122.06% |
| Sep 30, 2023 | 50.77% |
| Jun 30, 2023 | 38.38% |
| Mar 31, 2023 | 157.33% |
| Dec 31, 2022 | 29.24% |
| Sep 30, 2022 | -6.78% |
| Jun 30, 2022 | -125.35% |
| Mar 31, 2022 | -48.56% |
| Dec 31, 2021 | -127.04% |
| Sep 30, 2021 | -594.41% |
| Jun 30, 2021 | 6,461.17% |